The global liquid biopsy market size was estimated at USD 11.85 billion in 2024 and is projected to reach USD 22.88 billion by 2030, growing at a CAGR of 11.5% from 2025 to 2030. The market is experiencing significant expansion due to several critical factors. Chief among them is the rising global incidence of cancer, which continues to drive the demand for effective, efficient, and non-invasive diagnostic tools. In parallel, continuous technological advancements in cancer diagnostics are enhancing the capabilities and accuracy of liquid biopsy techniques, making them increasingly favorable in clinical settings. Furthermore, there is a notable trend toward minimally invasive diagnostic procedures, both from the perspective of patients and healthcare professionals, which is contributing to the growing adoption of liquid biopsies.

In addition to these primary growth drivers, the market is also benefiting from ongoing research and development efforts focused on creating innovative liquid biopsy assays and testing platforms. These efforts are being supported by the increasing use and development of multi-cancer early detection (MCED) tests, which represent a major opportunity for broadening the scope and application of liquid biopsy technologies across different cancer types and stages.

Liquid biopsy itself is a cutting-edge diagnostic technology that enables the detection of genetic mutations and alterations associated with tumors through a simple blood sample. This non-invasive approach is also instrumental in tumor stratification, which helps in tailoring precise, individualized cancer treatment strategies. For example, in January 2023, Guardant Health achieved a significant milestone when the U.S. Food and Drug Administration (FDA) approved its Guardant360 CDx liquid biopsy assay as a companion diagnostic tool for identifying ESR1 mutations in breast cancer patients. Such regulatory approvals, along with continuous innovation, product development, and expansion in the liquid biopsy sector, are collectively advancing the market and reinforcing its growing importance in the oncology diagnostics landscape.

Key Market Trends Insights:

• In 2024, North America emerged as the dominant region in the global liquid biopsy market, capturing the largest revenue share of 51.15%. This strong regional performance is largely attributed to the well-established healthcare infrastructure, higher awareness and adoption of advanced diagnostic technologies, and a strong presence of key market players. Within North America, the United States held the largest share of market revenue, further reinforcing the region's leadership position. The U.S. market benefits from substantial investments in cancer research, favorable reimbursement policies, and widespread clinical adoption of liquid biopsy technologies.

• From a technological standpoint, the multi-gene parallel analysis segment, also known as next-generation sequencing (NGS), led the liquid biopsy market in 2024 with the highest revenue share of 76.17%. This dominance is primarily due to NGS’s ability to simultaneously analyze multiple genetic alterations, enabling comprehensive profiling of tumors with greater precision and efficiency.

• In terms of biomarkers, the circulating tumor cells (CTC) segment accounted for the largest revenue share, representing 35.67% of the market in 2024. CTCs provide valuable insights into tumor biology and are widely used for cancer diagnosis, prognosis, and monitoring disease progression, contributing significantly to their strong market presence.

• When examined by application, the cancer segment overwhelmingly led the market with the highest revenue share of 86.31% in 2024. This significant share underscores the core focus of liquid biopsy technologies in oncology, particularly for early detection, treatment selection, and monitoring of various cancer types in a non-invasive manner.

Order a free sample PDF of the Liquid Biopsy Market Intelligence Study, published by Grand View Research.

Market Size Forecast:

• 2024 Market Size: USD 11.85 Billion

• 2030 Projected Market Size: USD 22.88 Billion

• CAGR (2025-2030): 11.5%

• North America: Largest market in 2024

Key Companies Market Share Insights:

The liquid biopsy industry is characterized by a dynamic mix of well-established market leaders and fast-growing emerging innovators, all of whom are actively employing diverse strategies to strengthen their market presence. Prominent companies such as ANGLE plc, Oncimmune Holdings PLC, Guardant Health, Myriad Genetics, Inc., Biocept, Inc., Lucence Health Inc., Freenome Holdings, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., and Epigenomics AG have maintained a competitive edge in the industry through a continuous focus on research and development, frequent product innovations, and expansion initiatives.

These key players leverage strategic approaches such as the development of advanced diagnostic tests, mergers and acquisitions, and collaborative partnerships with other biotech firms, healthcare providers, and research institutions. These efforts are designed not only to broaden their diagnostic portfolios but also to strengthen their global footprint and provide more comprehensive solutions to the growing demand for minimally invasive cancer diagnostics.

A notable example of such innovation can be seen in November 2023, when Illumina Inc. announced the launch of the TruSight Oncology 500 ctDNA v2, an upgraded version of its liquid biopsy assay. This new generation test is specifically designed for comprehensive genomic profiling using circulating tumor DNA (ctDNA), reflecting the industry's commitment to advancing precision oncology through improved molecular testing solutions.

Key Players

• ANGLE plc

• Oncimmune Holdings PLC

• Guardant Health

• Myriad Genetics, Inc.

• Biocept, Inc.

• Lucence Health Inc.

• Freenome Holdings, Inc.

• F. Hoffmann-La Roche Ltd.

• QIAGEN

• Illumina, Inc.

• Thermo Fisher Scientific, Inc.

• Epigenomics AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The liquid biopsy industry is expected to continue its rapid expansion—driven by increasing cancer incidence, demographic shifts toward an aging population, and the growing preference for minimally invasive diagnostics. Technological advances, particularly in early detection tools and genomic profiling technologies, are enhancing clinical uptake. Support from regulatory agencies and research funding further propels market development, creating a favorable environment for sustained growth and innovation in liquid biopsy testing.